Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy
Journal of Clinical Investigation · 15.09.2023 · 133 (18)
DOI: 10.1172/jci166275 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.09.2023. Verfasst von Sophie Karolczak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Myopathies, Structural, Congenital, Zebrafish. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Astellas Pharma US.
Abstract (Originalsprache)
X-linked myotubular myopathy (XLMTM) is a fatal congenital disorder caused by mutations in the MTM1 gene. Currently, there are no approved treatments, although AAV8-mediated gene transfer therapy has shown promise in animal models and preliminarily in patients. However, 4 patients with XLMTM treated with gene therapy have died from progressive liver failure, and hepatobiliary disease has now been recognized more broadly in association with XLMTM. In an attempt to understand whether loss of MTM1 itself is associated with liver pathology, we have characterized what we believe to be a novel liver phenotype in a zebrafish model of this disease. Specifically, we found that loss-of-function mutations in mtm1 led to severe liver abnormalities including impaired bile flux, structural abnormalities of the bile canaliculus, and improper endosome-mediated trafficking of canalicular transporters. Using a reporter-tagged Mtm1 zebrafish line, we established localization of Mtm1 in the liver in association with Rab11, a marker of recycling endosomes, and canalicular transport proteins and demonstrated that hepatocyte-specific reexpression of Mtm1 could rescue the cholestatic phenotype. Last, we completed a targeted chemical screen and found that Dynasore, a dynamin-2 inhibitor, was able to partially restore bile flow and transporter localization to the canalicular membrane. In summary, we demonstrate, for the first time to our knowledge, liver abnormalities that were directly caused by MTM1 mutation in a preclinical model, thus establishing the critical framework for better understanding and comprehensive treatment of the human disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Department of Molecular Genetics, The University of Toronto, Toronto, Ontario, Canada.
- Division of Clinical and Metabolic Genetics and.
- Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
- Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Translational Science Laboratory, Milwaukee, Wisconsin, USA.
Förderung
- NIDDK NIH HHS
- Astellas Pharma US
Zitieren
APA
Karolczak, S., Deshwar, A. R., Aristegui, E., Kamath, B. M., Lawlor, M. W., Andreoletti, G., Volpatti, J., Ellis, J. L., Yin, C., & Dowling, J. J. (2023). Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy. Journal of Clinical Investigation, 133(18). https://doi.org/10.1172/jci166275
Vancouver
Karolczak S, Deshwar AR, Aristegui E, Kamath BM, Lawlor MW, Andreoletti G, et al. Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy. Journal of Clinical Investigation. 2023;133(18). doi:10.1172/jci166275
BibTeX
@article{Karolczak2023,
author = {Karolczak, Sophie and Deshwar, Ashish R and Aristegui, Evangelina and Kamath, Binita M and Lawlor, Michael W and Andreoletti, Gaia and Volpatti, Jonathan and Ellis, Jillian L and Yin, Chunyue and Dowling, James J},
title = {Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy},
journal = {Journal of Clinical Investigation},
year = {2023},
volume = {133},
number = {18},
doi = {10.1172/jci166275}
}
EUVIMED